{"title_page": "Melasma", "text_new": "{{Infobox medical condition (new)\n| name            = Melasma\n| synonyms        = \n| image           = Melasmablemish.jpg\n| caption         = \n| pronounce       = \n| field           = [[Dermatology]]\n|| symptoms        = \n| complications   = \n| onset           = \n| duration        = \n| types           = \n| causes          = \n| risks           = \n| diagnosis       = \n| differential    = \n| prevention      = \n| treatment       = \n| medication      = \n| prognosis       = \n| frequency       = \n| deaths          = \n}}\n'''Melasma''' (also known as '''chloasma faciei''',<ref name=\"Andrews\">James, William; Berger, Timothy; Elston, Dirk (2005). ''Andrews' Diseases of the Skin: Clinical Dermatology''. (10th ed.). Saunders. {{ISBN|0-7216-2921-0}}.</ref>{{rp|854}} or the '''mask of pregnancy'''<ref>{{cite journal |last1=Tunzi |first1=M |last2=Gray |first2=GR |title=Common skin conditions during pregnancy |journal=Am Fam Physician |volume=75 |issue=2 |pages=211\u201318 |date=January 2007 |pmid=17263216 |doi= |url=}}</ref> when present in [[pregnancy|pregnant women]]) is a tan or dark skin discoloration. Melasma is thought to be caused by sun exposure, genetic predisposition, hormone changes, and skin irritation.<ref name=AAD2017>{{Cite web| url = https://www.aad.org/public/diseases/color-problems/melasma| title = Melasma {{!}} American Academy of Dermatology| website = www.aad.org| access-date = 2016-02-25}}</ref> Although it can affect anyone, melasma is particularly common in women, especially pregnant women and those who are taking [[oral contraceptive|oral]] or patch [[contraceptive]]s or [[hormone replacement therapy]] (HRT) medications.<ref name=AAD2017/>\n\n==Signs and symptoms==\nThe symptoms of melasma are dark, irregular well demarcated hyperpigmented macules to patches. These patches often develop gradually over time. Melasma does not cause any other symptoms beyond the cosmetic discoloration.<ref name=\"AAD20172\">{{Cite web|url=https://www.aad.org/public/diseases/color-problems/melasma|title=Melasma {{!}} American Academy of Dermatology|website=www.aad.org|access-date=2016-02-25}}</ref> Patches can vary in size from 0.5 cm to larger than 10 cm depending on the person. The location of melasma can be categorized as centrofacial, malar, or mandibular. The most common is centrofacial in which patches appear on the cheeks, nose, upper lip, forehead, and chin. The mandibular category accounts for patches on the bilateral rami, while the malar location accounts for patches only on the nose and checks.<ref name=\":13\">{{Cite book|title=Manual of dermatologic therapeutics|last=Arndt, Kenneth A., 1936-|others=Hsu, Jeffrey T. S.|isbn=978-1-4698-7200-1|edition=Eighth|location=[Place of publication not identified]|oclc=953864747|date = 2014-02-05}}</ref>\n\n==Cause==\nMelasma is thought to be the stimulation of [[melanocyte]]s (cells in the [[epidermis|dermal]] layer which transfer a [[pigment, biology|pigment]] called melanin to the keratinocytes of skin) when the skin is exposed to ultraviolet light from the sun. Small amounts of sun exposure can make melasma return to the skin after it has faded, which is why people with melasma often get it again and again, particularly in the summer.<ref name=AAD2017/>\n\nPregnant women often get melasma, or chloasma, known as the mask of pregnancy. Birth control pills and hormone replacement medicine also can trigger melasma. The discoloration usually disappears spontaneously over a period of several months after giving birth or stopping the oral contraceptives or hormone replacement therapy.<ref name=AAD2017/>\n\nGenetic predisposition is also a major factor in determining whether someone will develop melasma. People with the Fitzpatrick skin type III or greater from African, Asian, or Hispanic descent are at a much higher risk than others.<ref name=\":13\" /> In addition women with a light brown skin type who are living in regions with intense sun exposure are particularly susceptible to developing this condition.<ref name=\"AAD20175\">{{Cite web|url=https://www.aad.org/public/diseases/color-problems/melasma|title=Melasma {{!}} American Academy of Dermatology|website=www.aad.org|access-date=2016-02-25}}</ref>\n\nThe incidence of melasma also increases in patients with [[thyroid disease]].<ref>{{Cite journal | pmid = 3923030| year = 1985| last1 = Lutfi| first1 = R. J.| title = Association of melasma with thyroid autoimmunity and other thyroidal abnormalities and their relationship to the origin of the melasma| journal = The Journal of Clinical Endocrinology and Metabolism| volume = 61| issue = 1| pages = 28\u201331| last2 = Fridmanis| first2 = M| last3 = Misiunas| first3 = A. L.| last4 = Pafume| first4 = O| last5 = Gonzalez| first5 = E. A.| last6 = Villemur| first6 = J. A.| last7 = Mazzini| first7 = M. A.| last8 = Niepomniszcze| first8 = H| doi = 10.1210/jcem-61-1-28}}</ref> It is thought that the overproduction of [[melanocyte-stimulating hormone]] (MSH) brought on by stress can cause outbreaks of this condition. Other rare causes of melasma include allergic reaction to medications and cosmetics.\n\nMelasma Suprarenale ''(Latin - above the kidneys)'' is a symptom of [[Addison's disease]], particularly when caused by pressure or minor injury to the skin, as discovered by Dr. FJJ Schmidt of Rotterdam in 1859.\n\n==Diagnosis==\nThere are two different kinds of melasma, epidermal and dermal. Epidermal melasma results from melanin pigment that is elevated in the suprabasal layers of the epidermis. Dermal melasma occurs when the dermal macrophages have an elevated melanin level.<ref name=\":02\">{{Cite book|title=Evidence-based dermatology|others=Williams, Hywel C.,, Bigby, Michael E.|isbn=978-1-118-35762-0|edition=Third|location=Chichester, West Sussex|oclc=867001321|date = 2014-06-05}}</ref> Melasma is usually diagnosed visually or with assistance of a [[Wood's lamp]] (340 - 400&nbsp;nm wavelength).<ref name=\"AAD201722\">{{Cite web|url=https://www.aad.org/public/diseases/color-problems/melasma|title=Melasma {{!}} American Academy of Dermatology|website=www.aad.org|access-date=2016-02-25}}</ref> Under [[Wood's lamp]], excess [[melanin]] in the epidermis can be distinguished from that of the dermis. This is done by looking at how dark the melasma appears, dermal melasma will appear darker than epidermal melasma under the Wood's lamp.<ref name=\":02\" />\n\n===Differential diagnosis===\n*Post inflammatory hyperpigmentation\n*Actinic lichen planus\n*Hydroquinone-induced exogenous ochronosis (see [[Ochronosis#Treatments of Exogenous Ochronosis]])\n\n==Treatment==\n[[File:Laser Melasma Treatment.jpg|alt=Doctor performing treatment for melasma with KTP laser|thumb|Doctor performing treatment for melasma with KTP laser]]\n\nAssessment by a dermatologist will help guide treatment. Treatments to hasten the fading of the discolored patches include:\n\n* Topical depigmenting agents, such as [[hydroquinone]] (HQ) either in over-the-counter (2%) or prescription (4%) strength.<ref name=\":0\">{{cite journal |last1=Jutley |first1=Gurpreet Singh |last2=Rajaratnam |first2=Ratna |last3=Halpern |first3=James |last4=Salim |first4=Asad |last5=Emmett |first5=Charis |date=2014-02-01 |title=Systematic review of randomized controlled trials on interventions for melasma: an abridged Cochrane review |journal=Journal of the American Academy of Dermatology |volume=70 |issue=2 |pages=369\u2013373 |doi=10.1016/j.jaad.2013.07.044 |issn=1097-6787 |pmid=24438951}}</ref> HQ is a chemical that inhibits tyrosinase, an enzyme involved in the production of [[melanin]].\n* [[Tretinoin]],<ref name=\":1\">{{cite journal |last1=Rivas |first1=Shelly |last2=Pandya |first2=Amit G. |date=2013-10-01 |title=Treatment of melasma with topical agents, peels and lasers: an evidence-based review |journal=American Journal of Clinical Dermatology |volume=14 |issue=5 |pages=359\u2013376 |doi=10.1007/s40257-013-0038-4 |issn=1179-1888 |pmid=23881551}}</ref> an [[acid]] that increases skin cell (keratinocyte) turnover. This treatment is not used during pregnancy due to risk of harm to the fetus.\n* [[Azelaic acid]] (20%), thought to decrease the activity of melanocytes.<ref name=AAD2017/>\n* Tranexamic acid by mouth has shown to provide rapid and sustained lightening in melasma by decreasing melanogenesis in epidermal melanocytes.\n* Cysteamine hydrochloride (5%) over-the-counter.<ref>{{cite journal |last1=Mansouri |first1=P. |last2=Farshi |first2=S. |last3=Hashemi |first3=Z. |last4=Kasraee |first4=B. |date=2015-07-01|title=Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: a randomized double-blind placebo-controlled trial |journal=British Journal of Dermatology |language=en |volume=173 |issue=1 |pages=209\u2013217 |doi=10.1111/bjd.13424 |pmid=25251767 |issn=1365-2133}}</ref><ref>{{cite journal |last1=Bleehen |first1=S. S. |last2=Pathak |first2=M. A. |last3=Hori |first3=Y. |last4=Fitzpatrick |first4=T. B. |date=1968-02-01 |title=Depigmentation of skin with 4-isopropylcatechol, mercaptoamines, and other compounds |journal=The Journal of Investigative Dermatology |volume=50 |issue=2 |pages=103\u2013117 |issn=0022-202X |pmid=5641641 |doi=10.1038/jid.1968.13}}</ref> Mechanism of action seems to involve inhibition of melanin synthesis pathway<ref>{{cite journal |last1=Qiu |first1=L. |last2=Zhang |first2=M. |last3=Sturm |first3=R. A. |last4=Gardiner |first4=B. |last5=Tonks |first5=I. |last6=Kay |first6=G. |last7=Parsons |first7=P. G. |date=2000-01-01 |title=Inhibition of melanin synthesis by cystamine in human melanoma cells |journal=The Journal of Investigative Dermatology |volume=114 |issue=1 |pages=21\u201327 |doi=10.1046/j.1523-1747.2000.00826.x |issn=0022-202X |pmid=10620110}}</ref>\n*Kojic acid (2%) over-the-counter.<ref name=\":13\" />\n* Flutamide (1%)<ref>{{cite journal |last1=Adalatkhah |first1=Hassan |last2=Sadeghi-Bazargani |first2=Homayoun |date=2015-01-01 |title=The first clinical experience on efficacy of topical flutamide on melasma compared with topical hydroquinone: a randomized clinical trial |journal=Drug Design, Development and Therapy |volume=9 |pages=4219\u20134225 |doi=10.2147/DDDT.S80713 |issn=1177-8881 |pmc=4531037 |pmid=26345129}}</ref>\n* [[Chemical peels]]<ref>{{cite journal |last1=Chaudhary |first1=Savita |last2=Dayal |first2=Surabhi |date=2013-10-01 |title=Efficacy of combination of glycolic acid peeling with topical regimen in treatment of melasma |journal=Journal of Drugs in Dermatology: JDD |volume=12 |issue=10 |pages=1149\u20131153 |issn=1545-9616 |pmid=24085051}}</ref>\n* Microdermabrasion to dermabrasion (light to deep)\n* Galvanic or ultrasound facials with a combination of a topical cr\u00e8me/gel. Either in an aesthetician's office or as a home massager unit.\n* [[Photorejuvenation|Laser]] but not [[Intense pulsed light|IPL]] (IPL can make the melasma darker)\n\nEvidence-based reviews found that the most effective therapy for melasma includes a combination of topical agents.<ref name=\":1\" /><ref name=\":0\" /> Triple combination creams formulated with [[hydroquinone]], [[tretinoin]] and a steroid component have shown to be more effective than dual combination therapy or hydroquinone alone.<ref>{{Cite journal|last=Rajaratnam|first=Ratna|last2=Halpern|first2=James|last3=Salim|first3=Asad|last4=Emmett|first4=Charis|date=2010-07-07|title=Interventions for melasma|url=http://www.cochrane.org/CD003583/SKIN_treatments-for-melasma-darker-than-normal-skin-occurring-in-patches|journal=Cochrane Database of Systematic Reviews|issue=7|pages=CD003583|language=en|doi=10.1002/14651858.CD003583.pub2|pmid=20614435|issn=1465-1858}}</ref> More recently, a systematic review found that oral medications also have a role in melasma treatment, and have been shown to be efficacious with a minimal number and severity of adverse events. Oral medications and dietary supplements employed in the treatment of melasma include [[tranexamic acid]], ''[[Polypodium leucotomos]]'' extract, beta\u2010carotenoid, [[melatonin]], and [[procyanidin]].<ref>{{Cite journal|last=Zhou|first=Linghong Linda|last2=Baibergenova|first2=Akerke|date=2017-09-01|title=Melasma: systematic review of the systemic treatments|journal=International Journal of Dermatology|language=en|volume=56|issue=9|pages=902\u2013908|doi=10.1111/ijd.13578|pmid=28239840|issn=1365-4632}}</ref> Oral procyanidin combined with vitamins A, C, and E shows promise as safe and effective for epidermal melasma. In an 8-week randomized, double-blind, placebo-controlled trial in 56 Filipino women, treatment was associated with significant improvements in the left and right malar regions, and was safe and well tolerated.<ref>{{Cite journal|last=Handog|first=Evangeline|date=2009-07-20|title=A randomized, double-blind, placebo-controlled trial of oral procyanidin with Vitamins A, C, E for melasma among Filipino women|journal=International Journal of Dermatology|volume=48|issue=8|pages=896\u2013901|doi=10.1111/j.1365-4632.2009.04130.x|pmid=19659873}}</ref>\n\nIn all of these treatments the effects are gradual and a strict avoidance of sunlight is required. The use of broad-spectrum sunscreens with physical blockers, such as titanium dioxide and zinc dioxide is preferred over that with only chemical blockers. This is because UV-A, UV-B and visible lights are all capable of stimulating [[Pigment, biology|pigment]] production.\n\nThere are many negative side effects that go along with these treatments and many times treatments are unsatisfying overall. Things such as scarring, irritation, lighter patches of skin, and contact dermatitis are all commonly seen to occur.<ref name=\":02\" />\n\nPatients should avoid other precipitants including hormonal triggers.\n\n[[Cosmetic camouflage]] can also be used to hide melasma.\n\n==See also==\n*[[Linea nigra]]\n*[[Hyperpigmentation]] in [[Addison's disease]]\n*[[List of cutaneous conditions]]\n\n==References==\n{{Reflist}}\n\n== External links ==\n{{Medical resources\n| DiseasesDB      = 2402\n| ICD10           = {{ICD10|L|81|1|l|80}}\n| ICD9            = {{ICD9|709.09}}\n| ICDO            = \n| OMIM            = \n| MedlinePlus     = 000836\n| eMedicineSubj   = derm\n| eMedicineTopic  = 260\n| MeshID          = D008548\n| SNOMED CT       = 36209000\n}}\n*{{DermNet|colour/melasma}}\n\n{{Diseases of the skin and appendages by morphology}}\n{{Pigmentation disorders}}\n{{Pregnancy}}\n{{Pathology of pregnancy, childbirth and the puerperium}}\n{{Infants and their care}}\n\n[[Category:Disturbances of human pigmentation]]\n[[Category:Human pregnancy]]\n", "text_old": "{{Infobox medical condition (new)\n| name            = Melasma\n| synonyms        = \n| image           = Melasmablemish.jpg\n| caption         = \n| pronounce       = \n| field           = [[Dermatology]]\n|| symptoms        = \n| complications   = \n| onset           = \n| duration        = \n| types           = \n| causes          = \n| risks           = \n| diagnosis       = \n| differential    = \n| prevention      = \n| treatment       = \n| medication      = \n| prognosis       = \n| frequency       = \n| deaths          = \n}}\n'''Melasma''' (also known as '''chloasma faciei''',<ref name=\"Andrews\">James, William; Berger, Timothy; Elston, Dirk (2005). ''Andrews' Diseases of the Skin: Clinical Dermatology''. (10th ed.). Saunders. {{ISBN|0-7216-2921-0}}.</ref>{{rp|854}} or the '''mask of pregnancy'''<ref>{{cite journal |last1=Tunzi |first1=M |last2=Gray |first2=GR |title=Common skin conditions during pregnancy |journal=Am Fam Physician |volume=75 |issue=2 |pages=211\u201318 |date=January 2007 |pmid=17263216 |doi= |url=}}</ref> when present in [[pregnancy|pregnant women]]) is a tan or dark skin discoloration. Melasma is thought to be caused by sun exposure, genetic predisposition, hormone changes, and skin irritation.<ref name=AAD2017>{{Cite web| url = https://www.aad.org/public/diseases/color-problems/melasma| title = Melasma {{!}} American Academy of Dermatology| website = www.aad.org| access-date = 2016-02-25}}</ref> Although it can affect anyone, melasma is particularly common in women, especially pregnant women and those who are taking [[oral contraceptive|oral]] or patch [[contraceptive]]s or [[hormone replacement therapy]] (HRT) medications.<ref name=AAD2017/>\n\n==Signs and symptoms==\nThe symptoms of melasma are dark, irregular well demarcated hyperpigmented macules to patches. These patches often develop gradually over time. Melasma does not cause any other symptoms beyond the cosmetic discoloration.<ref name=\"AAD20172\">{{Cite web|url=https://www.aad.org/public/diseases/color-problems/melasma|title=Melasma {{!}} American Academy of Dermatology|website=www.aad.org|access-date=2016-02-25}}</ref> Patches can vary in size from 0.5 cm to larger than 10 cm depending on the person. The location of melasma can be categorized as centrofacial, malar, or mandibular. The most common is centrofacial in which patches appear on the cheeks, nose, upper lip, forehead, and chin. The mandibular category accounts for patches on the bilateral rami, while the malar location accounts for patches only on the nose and checks.<ref name=\":13\">{{Cite book|title=Manual of dermatologic therapeutics|last=Arndt, Kenneth A., 1936-|others=Hsu, Jeffrey T. S.|isbn=978-1-4698-7200-1|edition=Eighth|location=[Place of publication not identified]|oclc=953864747|date = 2014-02-05}}</ref>\n\n==Cause==\nMelasma is thought to be the stimulation of [[melanocyte]]s (cells in the [[epidermis|dermal]] layer which transfer a [[pigment, biology|pigment]] called melanin to the keratinocytes of skin) when the skin is exposed to ultraviolet light from the sun. Small amounts of sun exposure can make melasma return to the skin after it has faded, which is why people with melasma often get it again and again, particularly in the summer.<ref name=AAD2017/>\n\nPregnant women often get melasma, or chloasma, known as the mask of pregnancy. Birth control pills and hormone replacement medicine also can trigger melasma. The discoloration usually disappears spontaneously over a period of several months after giving birth or stopping the oral contraceptives or hormone replacement therapy.<ref name=AAD2017/>\n\nGenetic predisposition is also a major factor in determining whether someone will develop melasma. People with the Fitzpatrick skin type III or greater from African, Asian, or Hispanic descent are at a much higher risk than others.<ref name=\":13\" /> In addition women with a light brown skin type who are living in regions with intense sun exposure are particularly susceptible to developing this condition.<ref name=\"AAD20175\">{{Cite web|url=https://www.aad.org/public/diseases/color-problems/melasma|title=Melasma {{!}} American Academy of Dermatology|website=www.aad.org|access-date=2016-02-25}}</ref>\n\nThe incidence of melasma also increases in patients with [[thyroid disease]].<ref>{{Cite journal | pmid = 3923030| year = 1985| last1 = Lutfi| first1 = R. J.| title = Association of melasma with thyroid autoimmunity and other thyroidal abnormalities and their relationship to the origin of the melasma| journal = The Journal of Clinical Endocrinology and Metabolism| volume = 61| issue = 1| pages = 28\u201331| last2 = Fridmanis| first2 = M| last3 = Misiunas| first3 = A. L.| last4 = Pafume| first4 = O| last5 = Gonzalez| first5 = E. A.| last6 = Villemur| first6 = J. A.| last7 = Mazzini| first7 = M. A.| last8 = Niepomniszcze| first8 = H| doi = 10.1210/jcem-61-1-28}}</ref> It is thought that the overproduction of [[melanocyte-stimulating hormone]] (MSH) brought on by stress can cause outbreaks of this condition. Other rare causes of melasma include allergic reaction to medications and cosmetics.\n\nMelasma Suprarenale ''(Latin - above the kidneys)'' is a symptom of [[Addison's disease]], particularly when caused by pressure or minor injury to the skin, as discovered by Dr. FJJ Schmidt of Rotterdam in 1859.\n\n==Diagnosis==\nThere are two different kinds of melasma, epidermal and dermal. Epidermal melasma results from melanin pigment that is elevated in the suprabasal layers of the epidermis. Dermal melasma occurs when the dermal macrophages have an elevated melanin level.<ref name=\":02\">{{Cite book|title=Evidence-based dermatology|others=Williams, Hywel C.,, Bigby, Michael E.|isbn=978-1-118-35762-0|edition=Third|location=Chichester, West Sussex|oclc=867001321|date = 2014-06-05}}</ref> Melasma is usually diagnosed visually or with assistance of a [[Wood's lamp]] (340 - 400&nbsp;nm wavelength).<ref name=\"AAD201722\">{{Cite web|url=https://www.aad.org/public/diseases/color-problems/melasma|title=Melasma {{!}} American Academy of Dermatology|website=www.aad.org|access-date=2016-02-25}}</ref> Under [[Wood's lamp]], excess [[melanin]] in the epidermis can be distinguished from that of the dermis. This is done by looking at how dark the melasma appears, dermal melasma will appear darker than epidermal melasma under the Wood's lamp.<ref name=\":02\" />\n\n===Differential diagnosis===\n*Post inflammatory hyperpigmentation\n*Actinic lichen planus\n*Hydroquinone-induced exogenous ochronosis (see [[Ochronosis#Treatments of Exogenous Ochronosis]])\n\n==Treatment==\n[[File:Laser Melasma Treatment.jpg|alt=Doctor performing treatment for melasma with KTP laser|thumb|Doctor performing treatment for melasma with KTP laser]]\n\nAssessment by a dermatologist will help guide treatment. Treatments to hasten the fading of the discolored patches include:\n\n* Topical depigmenting agents, such as [[hydroquinone]] (HQ) either in over-the-counter (2%) or prescription (4%) strength.<ref name=\":0\">{{cite journal |last1=Jutley |first1=Gurpreet Singh |last2=Rajaratnam |first2=Ratna |last3=Halpern |first3=James |last4=Salim |first4=Asad |last5=Emmett |first5=Charis |date=2014-02-01 |title=Systematic review of randomized controlled trials on interventions for melasma: an abridged Cochrane review |journal=Journal of the American Academy of Dermatology |volume=70 |issue=2 |pages=369\u2013373 |doi=10.1016/j.jaad.2013.07.044 |issn=1097-6787 |pmid=24438951}}</ref> HQ is a chemical that inhibits tyrosinase, an enzyme involved in the production of [[melanin]].\n* [[Tretinoin]],<ref name=\":1\">{{cite journal |last1=Rivas |first1=Shelly |last2=Pandya |first2=Amit G. |date=2013-10-01 |title=Treatment of melasma with topical agents, peels and lasers: an evidence-based review |journal=American Journal of Clinical Dermatology |volume=14 |issue=5 |pages=359\u2013376 |doi=10.1007/s40257-013-0038-4 |issn=1179-1888 |pmid=23881551}}</ref> an [[acid]] that increases skin cell (keratinocyte) turnover. This treatment is not used during pregnancy due to risk of harm to the fetus.\n* [[Azelaic acid]] (20%), thought to decrease the activity of melanocytes.<ref name=AAD2017/>\n* Tranexamic acid by mouth has shown to provide rapid and sustained lightening in melasma by decreasing melanogenesis in epidermal melanocytes.\n* Cysteamine hydrochloride (5%) over-the-counter.<ref>{{cite journal |last1=Mansouri |first1=P. |last2=Farshi |first2=S. |last3=Hashemi |first3=Z. |last4=Kasraee |first4=B. |date=2015-07-01|title=Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: a randomized double-blind placebo-controlled trial |journal=British Journal of Dermatology |language=en |volume=173 |issue=1 |pages=209\u2013217 |doi=10.1111/bjd.13424 |pmid=25251767 |issn=1365-2133}}</ref><ref>{{cite journal |last1=Bleehen |first1=S. S. |last2=Pathak |first2=M. A. |last3=Hori |first3=Y. |last4=Fitzpatrick |first4=T. B. |date=1968-02-01 |title=Depigmentation of skin with 4-isopropylcatechol, mercaptoamines, and other compounds |journal=The Journal of Investigative Dermatology |volume=50 |issue=2 |pages=103\u2013117 |issn=0022-202X |pmid=5641641 |doi=10.1038/jid.1968.13}}</ref> Mechanism of action seems to involve inhibition of melanin synthesis pathway<ref>{{cite journal |last1=Qiu |first1=L. |last2=Zhang |first2=M. |last3=Sturm |first3=R. A. |last4=Gardiner |first4=B. |last5=Tonks |first5=I. |last6=Kay |first6=G. |last7=Parsons |first7=P. G. |date=2000-01-01 |title=Inhibition of melanin synthesis by cystamine in human melanoma cells |journal=The Journal of Investigative Dermatology |volume=114 |issue=1 |pages=21\u201327 |doi=10.1046/j.1523-1747.2000.00826.x |issn=0022-202X |pmid=10620110}}</ref>\n*Kojic acid (2%) over-the-counter.<ref name=\":13\" />\n* Flutamide (1%)<ref>{{cite journal |last1=Adalatkhah |first1=Hassan |last2=Sadeghi-Bazargani |first2=Homayoun |date=2015-01-01 |title=The first clinical experience on efficacy of topical flutamide on melasma compared with topical hydroquinone: a randomized clinical trial |journal=Drug Design, Development and Therapy |volume=9 |pages=4219\u20134225 |doi=10.2147/DDDT.S80713 |issn=1177-8881 |pmc=4531037 |pmid=26345129}}</ref>\n* [[Chemical peels]]<ref>{{cite journal |last1=Chaudhary |first1=Savita |last2=Dayal |first2=Surabhi |date=2013-10-01 |title=Efficacy of combination of glycolic acid peeling with topical regimen in treatment of melasma |journal=Journal of Drugs in Dermatology: JDD |volume=12 |issue=10 |pages=1149\u20131153 |issn=1545-9616 |pmid=24085051}}</ref>\n* Microdermabrasion to dermabrasion (light to deep)\n* Galvanic or ultrasound facials with a combination of a topical cr\u00e8me/gel. Either in an aesthetician's office or as a home massager unit.\n* [[Photorejuvenation|Laser]] but not [[Intense pulsed light|IPL]] (IPL can make the melasma darker)\n\nEvidence-based reviews found that the most effective therapy for melasma includes a combination of topical agents.<ref name=\":1\" /><ref name=\":0\" /> Triple combination creams formulated with [[hydroquinone]], [[tretinoin]] and a steroid component have shown to be more effective than dual combination therapy or hydroquinone alone.<ref>{{Cite journal|last=Rajaratnam|first=Ratna|last2=Halpern|first2=James|last3=Salim|first3=Asad|last4=Emmett|first4=Charis|date=2010-07-07|title=Interventions for melasma|url=http://www.cochrane.org/CD003583/SKIN_treatments-for-melasma-darker-than-normal-skin-occurring-in-patches|journal=Cochrane Database of Systematic Reviews|issue=7|pages=CD003583|language=en|doi=10.1002/14651858.CD003583.pub2|pmid=20614435|issn=1465-1858}}</ref> More recently, a systematic review found that oral medications also have a role in melasma treatment, and have been shown to be efficacious with a minimal number and severity of adverse events. Oral medications and dietary supplements employed in the treatment of melasma include [[tranexamic acid]], ''[[Polypodium leucotomos]]'' extract, beta\u2010carotenoid, [[melatonin]], and [[procyanidin]].<ref>{{Cite journal|last=Zhou|first=Linghong Linda|last2=Baibergenova|first2=Akerke|date=2017-09-01|title=Melasma: systematic review of the systemic treatments|journal=International Journal of Dermatology|language=en|volume=56|issue=9|pages=902\u2013908|doi=10.1111/ijd.13578|pmid=28239840|issn=1365-4632}}</ref> Oral procyanidin combined with vitamins A, C, and E shows promise as safe and effective for epidermal melasma. In an 8-week randomized, double-blind, placebo-controlled trial in 56 Filipino women, treatment was associated with significant improvements in the left and right malar regions, and was safe and well tolerated.<ref>{{Cite journal|last=Handog|first=Evangeline|date=2009-07-20|title=A randomized, double-blind, placebo-controlled trial of oral procyanidin with Vitamins A, C, E for melasma among Filipino women|journal=International Journal of Dermatology|volume=48|issue=8|pages=896\u2013901|doi=10.1111/j.1365-4632.2009.04130.x|pmid=19659873}}</ref>\n\nIn all of these treatments the effects are gradual and a strict avoidance of sunlight is required. The use of broad-spectrum sunscreens with physical blockers, such as titanium dioxide and zinc dioxide is preferred over that with only chemical blockers. This is because UV-A, UV-B and visible lights are all capable of stimulating [[Pigment, biology|pigment]] production.\n\nThere are many negative side effects that go along with these treatments and many times treatments are unsatisfying overall. Things such as scarring, irritation, lighter patches of skin, and contact dermatitis are all commonly seen to occur.<ref name=\":02\" />\n\nPatients should avoid other precipitants including hormonal triggers.\n\n[[Cosmetic camouflage]] can also be used to hide melasma.\n\n==See also==\n*[[Linea nigra]]\n*[[Hyperpigmentation]] in [[Addison's disease]]\n*[[List of cutaneous conditions]]\n\n==References==\n{{Reflist}}\n\n== External links ==\n{{Medical resources\n|   DiseasesDB     = 2402\n|   ICD10          = {{ICD10|L|81|1|l|80}}\n|   ICD9           = {{ICD9|709.09}}\n|   ICDO           = \n|   OMIM           = \n|   MedlinePlus    = 000836\n|   eMedicineSubj  = derm\n|   eMedicineTopic = 260\n|   MeshID         = D008548\n}}\n*{{DermNet|colour/melasma}}\n\n{{Diseases of the skin and appendages by morphology}}\n{{Pigmentation disorders}}\n{{Pregnancy}}\n{{Pathology of pregnancy, childbirth and the puerperium}}\n{{Infants and their care}}\n\n[[Category:Disturbances of human pigmentation]]\n[[Category:Human pregnancy]]\n", "name_user": "Dismanet", "label": "safe", "comment": "Adding new medical resources.", "url_page": "//en.wikipedia.org/wiki/Melasma"}
